IRVINE, Calif., April 26 /PRNewswire-FirstCall/ -- Dermisonics, Inc. , a medical device company focused on the development of painless, needle-free drug-delivery technology, has completed a demonstration of a mass production system for ultrasonic transducers used in its U-Strip ultrasonic drug delivery technology.
The U-Strip patented electronic system uses a specialized form of ultrasound waves to enhance the delivery of drugs through the skin and into the bloodstream from a specially modified patch. Ultrasound is generated via transducers, which convert electronic signals into mechanical energy. The transducers used in the U-Strip design emit an alternating ultrasonic waveform, sawtooth to squarewave, as opposed to ordinary transducers, which emit only sine waves, and generate a tremendous amount of heat energy as a result. The alternating signal reduces the heating effect, which could damage a drug in a transdermal patch delivery system.
Until recently these transducers were hand made to exacting specifications. Dermisonics engineers have produced a manufacturing mold system, which can fabricate the Redding Generation-5 transducers, on an assembly line basis. This step is expected to dramatically improve transducer precision and anticipated to reduce manufacturing costs.
Inventor of Dermisonics’ technology and Executive VP, Bruce Redding states, “The mass production process for the Redding Generation-5 transducers significantly improves our cost structure on what is the most expensive component of the U-strip System and puts the system in a range more suitable for both our consumer products and our drug delivery applications.” Redding adds. “In order to enable the wide adoption of our technology, it will be necessary to prepare for the mass production of its components. Production capability of the U-Strip transducer devices is now in place.”
Dermisonics is currently recruiting recipients to proceed with a planned Human Pilot Trial-2 on its U-Strip(TM) delivery system for use with insulin on Type-2 adult diabetics.
About Dermisonics, Inc.
Dermisonics Inc. is a specialized medical and cosmetic device company focused on the ongoing development, testing and commercialization of a transdermal patch designed to facilitate the efficient, painless and needle- free delivery of heavy molecular drugs in humans. Its leading drug-delivery platform, the U-Strip(TM), incorporates a transdermal patch controlled by microelectronics and using safe, ultrasonic technology. Clinical tests have shown this system to be very effective in the transdermal delivery of Insulin. It is also well suited to deliver at least 175 other existing drugs that, at present, cannot be effectively delivered through the pores of the skin using conventionally available transdermal technology due to their large molecular size.
The Company is also dedicated to the development of other portable ultrasonic devices for applications in the medical or wound care (Antiseptic Wand) and skin care (U-Wand) fields.
For additional information see www.dermisonics.com North American Investor Relations Contact: International Market Trend Toll-Free North America 1-877-676-4447 European Investor Relations Contact: Michael Drepper Phone: +49-621-430-6130 investor-germany@dermisonics.com Legal Notice Regarding Forward-Looking Statements
Except for the historical information contained herein, this news release contains forward-looking statements regarding future events and the future performance of Dermisonics, Inc. that involve risks and uncertainties that could cause actual results to differ materially from those projected. Words such as “anticipates,” “believes,” “plans,” “expects,” “intends,” “future,” and similar expressions are intended to identify forward-looking statements. These risks and uncertainties are described in the Company’s supplemental filings with the U.S. Securities and Exchange Commission.
Dermisonics, Inc.
CONTACT: North American investor relations, International Market Trend,877-676-4447; or European investor relations, Michael Drepper,+49-621-430-6130, or investor-germany@dermisonics.com
Web site: http://www.dermisonics.com//
